Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
about
Self-report measures of medication adherence behavior: recommendations on optimal usePharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaFactors influencing adherence to cancer treatment in older adults with cancer: a systematic reviewThe growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABLHow will B-cell-receptor-targeted therapies change future CLL therapy?Tyrosine Kinase Inhibitors for the Treatment of Chronic-Phase Chronic Myeloid Leukemia: Long-Term Patient Care and ManagementOral antineoplastic agents: how do we care about adherence?The role of observational studies in optimizing the clinical management of chronic myeloid leukemiaSensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib eraMeasuring the symptom burden associated with the treatment of chronic myeloid leukemiaHow could patient reported outcomes improve patient management in chronic myeloid leukemia?Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study.Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report.Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitorsMeasuring symptoms as a critical component of drug development and evaluation in hematological diseasesMedication-related issues associated with adherence to long-term tyrosine kinase inhibitors for controlling chronic myeloid leukemia: a qualitative studyChronic Myeloid Leukemia in India.Interpreting molecular monitoring results and international standardization in chronic myeloid leukemia.Guide to interpreting disease responses in chronic myeloid leukemia.Optimizing adherence to adjuvant imatinib in gastrointestinal stromal tumor.Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.The use of erlotinib in daily practice: a study on adherence and patients' experiences.Advances in the treatment of chronic myeloid leukemia.Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review.Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.Oral anticancer agent medication adherence by outpatientsTrends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysisThe pharmacogenetics of imanitib.NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.
P2860
Q26775742-549C352B-A4E8-41EF-B2CD-42E3C1B2B572Q26781539-3F53168E-2C9E-4A08-9AB4-3B115753F0FDQ26850736-A6FADEFA-ABA6-4759-849E-A3C5D97CA9F7Q26866312-064DB97E-6CD6-4BDF-9CF1-A6CFEAD614E6Q27024187-C4B99E0C-8055-4B4B-B10F-7E21E5723BEFQ28075963-9ABE914D-FC00-43B2-8FDF-BD51531E158BQ28082909-41087EF2-ABA0-4233-BDC8-616545A25070Q28085149-93DBB38B-B6CC-433B-8FC6-A5F30482E71BQ28486093-8DD56E53-9511-4BDD-8C12-33A444E570D6Q28689231-339A5AC9-B553-4DC0-8692-503705B6607DQ30241092-633CBDE1-8BFB-4761-B80A-9C7C8F3B99F5Q30242015-7DAE4C13-568E-4700-AD52-574F4F8E5911Q33392977-4DEC389E-2794-4686-8EC3-243CF4646788Q33396265-A96E3981-CCCA-4A46-8AFD-628CB57ECB8EQ33397085-8CE235BE-31A1-48E8-8D15-22CFA043FEBEQ33402939-2CE2BD2D-9A96-4AF7-82CA-EB0B6E79600EQ33420661-6D603D03-D0AC-4EFF-8792-4CAD49084143Q33442587-6EBDBFE6-7B8A-455F-94B3-40FC4A35CC01Q33603379-249CDE80-A5F6-4398-9893-E53AB6303AEBQ33705743-1D60686D-D5C6-4405-914B-3E112D15641CQ33813279-08EC7D23-1F8D-4740-A9AF-FB99B7F31BDAQ33859551-EAFA0B2B-D974-443E-A5D5-C4352D60BC71Q33885583-9408AB96-DA74-4607-B201-AF72C7FC1028Q33885637-42B86A33-8F44-4E4C-AEC1-9389389279E4Q33885999-6D3F46FB-2936-4F7B-AC7B-E5EF65C33E61Q33903030-95F452D2-EC63-460D-9FFC-31ECD7B3107FQ33948681-E031F202-8E2A-4BDB-BA45-396E9380F276Q34002977-6857E3E3-8A30-4B4C-890B-DF6AE55E6375Q34055591-75730269-F886-48B2-9A1F-C82C43224F53Q34066197-DE27399D-8D0E-482F-81C6-FC28813AA1DFQ34272962-F35215D5-54CB-4E6C-A75E-AE8BE85D80B6Q34293339-5BC99583-8F4D-47E2-88CB-C9DF5F7B8961Q34445704-997958D7-9AFF-4EEC-926F-10B1E8B8A3FFQ34469295-89A2631F-41E2-406A-837E-70F120096B9DQ34522789-1CE57324-AFD6-4709-B598-32765CAAC1B7Q34525644-5C3A1FA6-BE11-401A-89DD-198B56A6664AQ34550540-924D134E-D621-4388-9372-BD9E36AD4404Q34599540-0CCB45B5-6A89-48DB-986A-741294BB9654Q34750582-86E6B2A2-2522-4250-8364-44BE0262D3F5Q34894883-717611A2-841D-427E-8B85-981DFD14760F
P2860
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Adherence is the critical fact ...... genetic responses on imatinib.
@en
Adherence is the critical fact ...... genetic responses on imatinib.
@nl
type
label
Adherence is the critical fact ...... genetic responses on imatinib.
@en
Adherence is the critical fact ...... genetic responses on imatinib.
@nl
prefLabel
Adherence is the critical fact ...... genetic responses on imatinib.
@en
Adherence is the critical fact ...... genetic responses on imatinib.
@nl
P2093
P921
P356
P1476
Adherence is the critical fact ...... ogenetic responses on imatinib
@en
P2093
Alexandra Bazeos
Alistair Reid
Christos Paliompeis
Cristina Guallar
David Marin
Dragana Milojkovic
Francois-Xavier Mahon
Hugues de Lavallade
Jamshid S Khorashad
Jane F Apperley
P304
P356
10.1200/JCO.2009.26.3087
P407
P577
2010-04-12T00:00:00Z